Merkoša sitáhtat
APA-čujuhus (7. p.)
Lan, M., Wang, T., Luo, D., Chen, Y., Liang, W., Kong, R., & Xie, Q. (2024). Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression. Frontiers Media S.A.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Lan, Meiling, Tianyun Wang, Diexiao Luo, Yan Chen, Wei Liang, Rui Kong, juo Qichao Xie. Application of Disitamab Vedotin in the Multiline Treatment of EGFR Mutation-positive Lung Adenocarcinoma with Her-2 Overexpression. Frontiers Media S.A, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Lan, Meiling, et al. Application of Disitamab Vedotin in the Multiline Treatment of EGFR Mutation-positive Lung Adenocarcinoma with Her-2 Overexpression. Frontiers Media S.A, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.